1	Title:					
2	Estimating the optimal age for infant measles vaccination					
3						
4	Authors:					
5	Elizabeth Goult ^{1, *}					
6	Laura Andrea Barrero Guevara ^{1,2}					
7	Michael Briga ¹					
8	Matthieu Domenech de Cellès ¹					
9						
10	1. Infectious Disease Epidemiology group, Max Planck Institute for Infection Biology,					
11	Charitéplatz 1, Campus Charité Mitte, 10117, Berlin, Germany					
12	2. Institute of Public Health, Charité-Universitätsmedizin Berlin, 10117, Berlin,					
13	Germany					
14						
15	* Corresponding author, email: goult@mpiib-berlin.mpg.de					

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract: (150 words)

18 The persistence of measles in many regions demonstrates large immunity gaps, resulting from 19 incomplete or ineffective immunization with measles-containing vaccines (MCVs). A key 20 factor affecting MCV impact is age, with infants receiving dose 1 (MCV1) at older ages having 21 a reduced risk of vaccine failure, but also an increased risk of contracting infection before 22 vaccination. Here, we designed a new method-based on a transmission model incorporating 23 realistic vaccination delays and age variations in MCV1 effectiveness-to capture this risk trade-off and estimate the optimal age for recommending MCV1. We predict a large 24 25 heterogeneity in the optimal ages (range: 6-20 months), contrasting the homogeneity of 26 observed recommendations worldwide. Furthermore, we show that the optimal age depends on 27 the local epidemiology of measles, with a lower optimal age predicted in populations suffering 28 higher transmission. Overall, our results suggest the scope for public health authorities to tailor 29 the recommended schedule for better measles control.

Main text: (4992 words)

32 Introduction: (724 words)

Measles is a highly contagious childhood infection¹ caused by the measles virus. The virus is primarily spread through respiratory droplets and aerosols², and symptoms include cough, fever, malaise, and a characteristic maculopapular rash¹. Historically, measles was a major childhood disease, infecting almost all individuals in early life³ and resulting in 2–3 million deaths per year¹. The introduction of measles vaccines in the 1960s significantly reduced the global number of measles cases and deaths⁴, with estimated deaths in 2021 reduced to approximately 128,000⁵.

40

41 However, despite the indisputable global success of the vaccine, measles remains endemic in 42 multiple countries. Many regional elimination targets for 2020 were not met⁶, reflecting the 43 difficulty of reaching the high immunization coverage needed for measles elimination⁴. These 44 difficulties were compounded during the COVID-19 pandemic, which caused interruptions in 45 routine vaccinations and supplementary immunization activities (SIAs)^{6,7}, resulting in new measles outbreaks in 18 countries⁶. Since 2020, 140 countries have reported at least 1 case per 46 47 year to the World Health Organization (WHO), and over 30 countries have reported over 1,000 cases in a year⁸. 48

49

Although the immunity gaps that drive continued measles transmission are mainly caused by insufficient vaccine coverage, they also result from vaccine failures. One avertable cause of these vaccine failures is the vaccination age: vaccination with the first dose of measlescontaining vaccine (MCV1) at younger ages results in a higher risk of vaccine failure⁹. Two main mechanisms have been proposed to explain this result: blunting by maternal antibodies and immaturity of the infant immune system^{10,11}. However, despite the potential consequences

on measles control – e.g., changing the recommended MCV1 age as a potential control
intervention – the impact of vaccination age on vaccine effectiveness (VE) has only recently
been quantified⁹.

59

As illustrated in Figure 1a, the increasing effectiveness of MCV1 with age should result in a 60 trade-off in risks when recommending MCV1 age: reducing the age of vaccination increases 61 62 the risk of vaccine failure, while increasing the age worsens the risk of infection before vaccination. Hence, by balancing these risks, the recommended MCV1 age may be optimized 63 64 to minimize measles incidence. Furthermore, location-specific factors, such as transmission 65 level, are expected to affect this trade-off by changing the mean age of infection (MAI), resulting in different optimal ages^{12,13}. Following this conceptual model, one expects the 66 67 optimal vaccination age to depend on the local epidemiology of measles.

68

69 As seen in Figure 2, however, the global homogeneity in recommended MCV1 ages contrasts with the observed heterogeneity in measles incidence¹⁴. The partial Spearman rank correlation 70 71 coefficient between MCV1 ages and countries' mean annual incidence was only -0.12 (p-72 value: 0.53) in countries with >1 measles case per 1 million per year, when controlling for 73 Human Development Index (HDI), an aggregate measure of countries' longevity, education, 74 and standard of living¹⁵. Of the 205 MCV1 recommendations obtained, 70% of 75 recommendations were at 9 months (69 countries) or 12 months (109 countries), reflecting the 76 recommendations from the WHO: MCV1 at 9 months in countries with ongoing transmission and at 12 months in countries with low transmission¹⁴. Although these recommendations 77 78 generally reflect the trade-off in risks, they may not capture the complexity of factors that impact measles epidemiology, such as further transmission variation driven by differences in 79 social contact patterns or vaccination coverage. 80

81

82 The relative homogeneity in MCV1 recommendations suggests opportunities for refining the 83 MCV1 age to leverage this risk trade-off. Here, we propose a new method—based on a 84 mechanistic model of endemic measles transmission incorporating realistic, data-driven models of MCV1 delay and VE variation with age-to estimate the optimal age to recommend 85 MCV1. As a proof of concept, we used this method to estimate the optimal MCV1 age in a 86 87 range of synthetic test populations. In these populations, we varied parameter values across realistic ranges to identify factors determining optimal age (Figure 1b). We show that a 88 89 mismatch between the optimal and recommended ages can potentially increase measles incidence. Furthermore, we show that the optimal age is sensitive to location-specific 90 91 determinants of measles epidemiology, with transmission level having the greatest effect, 92 followed by the social contact structure and vaccination coverage. Overall, our study suggests 93 that the optimal MCV1 age is highly population-specific and, hence, more heterogeneous than the current recommendations reflect. Our findings thus suggest the potential to adjust MCV1 94 95 ages to reduce measles incidence, taking steps toward eventual elimination.

96

97 Methods: (1,453 words)

98 Data on measles incidence, recommended MCV1 age, and the Human Development Index

We gathered data on MCV1 recommended age from the WHO¹⁶ and the European Centre for Disease Prevention and Control (ECDC)¹⁷, supplemented with reports from individual countries in cases of missing data^{18–23}. We also collected country-level estimates of annual measles incidence for 2010–2019 from the WHO¹² and HDI values for the same period from the United Nations Development Program¹⁵.

104

105 The relationship between MCV age and vaccine effectiveness

To quantify how vaccination age affects MCV VE, we fitted a statistical model to reported estimates of MCV VE, obtained from a systematic review⁹. For MCV1 VE, to reduce uncertainty in MCV1 age, we only included estimates with an MCV1 age interval of <3 months. For the included MCV1 VE estimates, we calculated each estimate's standard error from reported 95% confidence intervals²⁴.

111

We then fitted a shape-constrained additive model (SCAM)²⁵ to the logit-transformed MCV1 VE estimates. Specifically, we used a monotonically increasing P-spline basis with 4 knots, weighted according to precision, with standard errors transformed using the Delta method. We then calculated approximate simultaneous confidence intervals to assess uncertainty in model fit²⁶. To include this uncertainty in the transmission model, we considered 5 curves corresponding to the predicted 2.5%, 25%, 75%, and 97.5% quantiles and the maximum likelihood estimate (MLE) from the SCAM.

119

For MCV dose 2 (MCV2) VE, too few estimates were available to assess age dependencies
(Supplementary Figure 1). We, therefore, assumed MCV2 VE to be constant and equal to the
mean MCV2 VE.

123

124 <u>The distribution of MCV1 delay</u>

To incorporate realistic distributions of MCV delay (*i.e.*, the delay between the recommended age and the actual age of administration), we obtained data on MCV1 delay in 45 low and middle-income countries (LMICs)²⁷, where most measles deaths occur⁵. The data consisted of the observed 25%, 50%, and 75% quantiles of the delay distribution. We excluded any countries with negative median delay. We initially fitted an Exponential distribution, which failed to capture the observed long right tails. Hence, we then fitted a Lomax distribution²⁸ (an

extension of the Exponential distribution with longer right tails to capture long delays) to every
country by minimizing the squared distance between the simulated and observed quantiles. To
summarize the variation in delay distributions, we clustered the Lomax distribution parameters
using Partitioning Around Medoids (PAM) Euclidean distance clustering²⁹. The number of
clusters was determined using the average silhouette method³⁰ and the Gap statistic³¹, with 500
bootstraps.

137

138 Model of measles transmission and vaccination

To simulate measles incidence when recommending MCV1 at different ages, we constructed a mechanistic model of measles transmission and vaccination, incorporating the aforementioned data-driven statistical models of MCV1 delay and age-specific MCV1 VE. The model was a deterministic SIR model, which split the population by infection status into susceptible, infectious, recovered, and protected by maternal antibodies. For sufficiently large populations, deterministic models have been shown to capture the dynamics of measles^{32,33}.

145

The model was age-structured, to allow the vaccination age to vary. The model split the 146 147 population into monthly age groups between ages 0 to 59 months, then into 5-year age groups 148 between ages 5 to 79. We assumed a uniform age distribution and constant population size. 149 Contacts between age groups were parameterized using data-derived social contact matrices 150 (SCM)^{34,35}. To capture the variability in social contact structure, we selected 7 SCMs derived 151 from China, India, Japan, Moscow, South Africa, the UK, and the USA, representing the 152 clusters identified in a previous study that clustered SCMs from 35 countries and 277 153 subnational administrative regions³⁴.

155 To model vaccination with two doses of MCV, we added a vaccinated susceptible state to 156 model infants with primary vaccine failure (*i.e.*, infants who received the vaccine but failed to mount an effective immune response³⁶). Vaccination was assumed to occur when aging from 157 158 one age group to the next. For the first dose (MCV1), at a given age, individuals were either vaccinated or not vaccinated, determined by the recommended MCV1 age, delay distribution, 159 160 and MCV1 coverage. If unvaccinated, individuals entered the next age group's susceptible 161 compartment. If vaccinated, the probability of successful vaccination was determined by the 162 VE-age relationship. If successful, infants were protected and entered the recovered 163 compartment of the next age group. If unsuccessful, they remained unprotected and entered the 164 next age group's vaccinated-susceptible compartment. The process remained the same for 165 MCV2, but vaccination occurred when aging from the vaccinated susceptible compartment. 166 The recommended MCV2 age was modeled as 6 months after the recommended MCV1 age, aligning with the modal gap between reported MCV schedules^{16–23}. 167

168

Full model details, including parameterization, are included in the supplementary materials(Supplementary Table 1).

171

172 <u>Recapitulating reported pre-vaccine mean ages of measles infection</u>

To calibrate transmission parameters, we compared the simulated MAI with historical reports from the pre-vaccine era³⁷, which ranged from 24 months to 72 months (Supplementary Table 2). We grouped the MAI into three transmission levels: 48–72 months (low-transmission level), 36–48 months (medium-transmission level), and 24–36 months (high-transmission level). Based on the evidence of age heterogeneities in transmissibility^{38,39}, we incorporated a parameter (*q*) representing the transmissibility of <5-year-olds relative to \geq 5-year-olds. Finally, for a range of fixed R_0 values in the interval 10–20, we calibrated *q* by fitting the predicted

pre-vaccine MAI to 3 MAI target values (lower bound, mid-value, and upper bound) in each transmission level. For each target MAI, $5 R_0 - q$ pairs were selected, resulting in a total of 15 pairs for each transmission level.

183

The model was run assuming a constant population of 10 million for 500 years, at which point convergence to the equilibrium solution was determined by the magnitude of the derivatives⁴⁰. If this convergence criterion was not fulfilled, the final 20 years of the simulation were extracted, and a linear model fit to the modeled cases. The simulation was judged to have converged if the slope of the linear model was less than 10^{-3} per day, corresponding to a change of <1 case per year. If convergence was achieved, the modeled MAI was calculated and compared against the target MAI using the sum of squares.

191

192 <u>The optimal age to recommend MCV1</u>

We simulated recommending MCV1 at different ages, monthly from 6 to 20 months. For each recommended age, we calculated the corresponding annual incidence at equilibrium, then identified the MCV1 age that minimized the incidence aggregated over all age groups. Furthermore, to identify factors that have the greatest impact on the optimal age we varied these factors across realistic values (Figure 1b).

198

We simulated measles annual incidence using the model described above, simulating without vaccination for 50 years, then introducing vaccination and running the model for a further 950 years. Vaccination was modeled as beginning from the recommended MCV1 age, with delays in MCV1 and MCV2 following the delay distributions described above. The vaccine coverage was defined as the proportion of a birth cohort vaccinated by 24 months after the recommended MCV1 coverage from the WHO¹⁴, we set MCV1 coverage

at 45%, 55%, 65%, 75%, and 85%, and MCV2 coverage at 5% points lower than the set MCV1
coverage.

207

208 To assess variation in optimal ages, we estimated the optimal age for every combination of 209 SCM (China, India, Japan, Moscow, South Africa, UK, USA), vaccine coverage (MCV1 210 coverages: 45%, 55%, 65%, 75%, 85%), delay distribution (short delay and long delay), VE 211 curve (2.5%, 25%, 75%, 97.5% quantiles, and the MLE), and transmission level (low-, 212 medium-, and high-transmission, with 15 R_0-q pairs for each level), see Figure 1b. Any 213 combination that failed to converge to the equilibrium solution according to the 214 abovementioned convergence criteria, at any recommended MCV1 age, was removed. Optimal 215 ages were then calculated and compared. To facilitate this comparison and evaluate the current 216 WHO clustering of recommendations, we clustered (using PAM clustering²⁹ based on Euclidean distance, and the silhouette method³⁰ to determine cluster sizes) the estimated 217 218 optimal ages to identify groups of SCM.

219

220 <u>Numerical Implementation</u>

Analysis was carried out using R version 4.1.1⁴¹, using the R package "tidyverse"⁴². Partial 221 correlations were calculated using the package "ppcor"43. SCAMs were fitted using the 222 package "scam"⁴⁴. Lomax distributions were fitted using the R package "optim"⁴⁵, using the 223 algorithm "L-BFGS-B"46. PAM clustering was carried out using the R packages "cluster"47 224 and "factoextra"⁴⁸. The measles model was implemented in C and R, using the R package 225 "pomp"⁴⁹. Parameter fitting was carried out using the subplex algorithm⁵⁰, in the R package 226 227 "nloptr"⁵¹. Mixed-effect models were fitted using the package "lme4"⁵². Figures were created using the R packages "ggplot2"53, "viridis"54, "wesanderson"55, "patchwork"56, and "ggh4x"57. 228

230

Results: (1242 words)

232 MCV1 effectiveness increases with age of receipt

After applying our inclusion criteria, we analyzed a total of 52 VE estimates from 16 studies.
As shown in Figure 3a, the point estimates and the confidence intervals of VE varied greatly.
Lower ages displayed particularly high variation in VE estimates. A large part of the overall
variation was captured by the SCAM (59.3% of deviance explained), which estimated an
increase in VE with age, confirming the results of the earlier meta-analysis⁹. The SCAM
estimated the VE at 64.5% at 6 months, approaching 100% by 20 months. Hence, the model
confirms that, for infants ≤20 months, the effectiveness of MCV1 increases with age of receipt.

241 Empirical data on the reported age of vaccination reveal MCV1 is frequently delayed

Based on data from 43 countries that met our inclusion criteria, we found that delays in
receiving MCV1 were prevalent (median (range) of median delay: 0.6 (0.1, 1.3) months),
exceeding 3 months for 25% of infants in 9 countries (median (range) of 75% delay quantile:
1.8 (0.4, 5.6) months).

246

247 In 41 of the 43 countries, we successfully fitted the Lomax distribution (see Supplementary 248 Figure 2), which recapitulated the 50% and 75% quantiles of the observed delay distributions. 249 Using PAM clustering, we identified two broad groups of countries (Figure 2b, Supplementary 250 Figure 2): one group with longer right tails (long delay, 35 countries, medoid country: Uganda, 251 survey median (IQR): 0.6 (0, 2.2) months, model median (IQR): 0.6 (0.2, 2.2) months) and 252 another group with shorter right tails (short delay, 5 countries, medoid country: Turkey, survey median (IQR): 0.7 (0.2, 1.6) months, model median (IQR): 0.7 (0.2, 1.6) months). For both 253 254 clusters and all observed countries, the estimated parameters resulted in median delays in the

range 0.1 to 1.3 months, corresponding to a median delay of up to 14% when MCV1 was recommended at 9 months. Taken together, this analysis indicates MCV1 is frequently delayed, with important implications for measles control by vaccination, modeling the transmission dynamics of measles, and estimating the optimal age of MCV1.

259

By combining the delay distribution with age-specific MCV1 effectiveness, we calculated the 260 261 cumulative effective vaccine coverage, defined as the proportion of a birth cohort protected by the vaccine by a given age (Figure 2c). This effective coverage reflected the conceptual trade-262 263 off in risks outlined in Figure 1a: increasing the recommended MCV1 age left a birth cohort 264 susceptible to infection for longer but also increased MCV1 effectiveness and, hence, the longterm proportion of the cohort protected. Furthermore, the delay distribution also determined 265 266 the effective coverage, with longer delays resulting in lower proportions of a birth cohort protected 18 months after the recommended age (Figure 2d). 267

268

269 <u>Heterogeneity in transmissibility is necessary to recapitulate pre-vaccine reports of measles</u>
 270 <u>MAI</u>

271 When comparing model-derived MAIs to historical estimates in the pre-vaccine era, we found that, for typically reported values of R_0^{58} between 12 and 18, the model failed to recapitulate 272 273 the MAIs for multiple SCMs (Supplementary Figure 5). However, once age-specific 274 transmissibility was included, the transmission model could recapitulate all historical estimates 275 of MAIs for all SCMs, except the Chinese SCM for a MAI of 24 months. All fitted values of q and R_0 converged according to the convergence criteria. These fitted pairs displayed a 276 277 negative association, such that increases in R_0 were compensated by decreases in q. Hence, this calibration allowed us to define parameter regions that reproduce each transmission level 278 279 (Figure 4) for inclusion in the transmission model.

280

281 <u>The optimal age to recommend MVC1 is sensitive to transmission level, contact structure, and</u> 282 vaccine coverage

283 Of all the parameter sets modeled, 99.4% fulfilled our convergence criteria. Across those, we identified a unique optimal age ranging between scenarios from 6 to 20 months. Furthermore, 284 285 the predicted optimal ages varied greatly between scenarios (see Figure 5a-b). For example, 286 the optimal age for the low-transmission level with the China SCM at 85% MCV1 coverage 287 ranged from 15 to 20 months, whereas the high-transmission level at 45% vaccine coverage 288 with the South Africa SCM ranged from 6 to 7 months. Moreover, recommending a non-289 optimal MCV1 age on incidence could result in up to a 2.6-fold increase in incidence, although 290 the impact of an age mismatch was similarly scenario-dependent (see Figure 5a, Table 1).

291

Of the factors we varied, the transmission level impacted the optimal age the most. At 45% 292 293 MCV1 coverage, parameterized with the USA SCM, the optimal age ranged between 11 to 13 294 months in a low-transmission setting and 7 to 9 months in a high-transmission setting. More generally, increasing transmission from low to medium decreased the optimal age by an 295 296 average of 1.6 months, and increasing from low to high transmission resulted in an average 297 decrease of 3.6 months (Supplementary Table 3). Higher transmission resulted in lower MAIs 298 and increased the risk of infection at younger ages, thus resulting in younger optimal ages to 299 compensate for this risk. Accordingly, increases in the pre-vaccine MAIs resulted in increases 300 in the optimal age (Supplementary Figure 6a). After controlling for the MAI, the additional 301 impact of R_0 and q on the optimal age was minimal (data not shown).

302

303 Social contact structure also affected the optimal age to recommend MCV1. Even after 304 controlling for transmission level and vaccine coverage, the range of optimal ages varied

305 between SCMs: for example, from 6 to 7 months for the South Africa SCM to 9 to 12 months 306 for the China SCM for a scenario with high transmission at 45% coverage. Depending on the 307 MCV coverage-transmission level scenario considered, the optimal ages clustered into 2-5 308 groups. However, ≥ 3 groups were typically required to capture the heterogeneity in optimal 309 ages between SCMs (13/15 scenarios, Supplementary Figure 7). In most scenarios, the China 310 SCM and the South Africa SCM tended to cluster independently, representing the SCMs with 311 the oldest and youngest optimal ages respectively, with other SCMs clustering together, with 312 optimal ages between these groups.

313

314 Finally, vaccine coverage also impacted the optimal age. Specifically, increased coverage 315 reduced measles incidence, resulting in higher optimal ages. For example, optimal MCV1 ages 316 in a low-transmission setting with the South Africa SCM ranged from 7 to 11 months at 45% 317 vaccine coverage and from 11 to 15 months at 85% vaccine coverage. In general, when 318 accounting for transmission level and SCM, a 10-percentage point increase in MCV1 coverage 319 resulted in an average increase in optimal age of 0.8 months (Supplementary Table 4). Overall, 320 these results demonstrate the importance of location-specific factors of measles epidemiology 321 for vaccine policy.

322

323 <u>The impact of variations in age-specific MCV1 effectiveness and delay distribution on the</u> 324 <u>optimal age is minor</u>

Uncertainty in the vaccine effectiveness curve only marginally affected the optimal age. When holding all other parameters constant, varying the curve resulted in changes in the optimal age in only 12.0% of parameter sets. In cases where the optimal age varied, the effect was inconsistent, but generally, as the quantile of the VE curve increased, the optimal age decreased (Supplementary Figure 6b).

330

Uncertainty in the MCV delay distribution had a similarly minor impact on optimal age. When
holding all other parameters fixed, changing the delay distribution resulted in a change in
optimal age in only 14.6% of parameter sets. When changes occurred, a higher optimal age
was predicted for the short delay distribution (Supplementary Figure 6c).

335

336 Discussion: (1057 words)

337 In this study, we developed a new method, based on a mechanistic model of measles 338 transmission and vaccination, to estimate the optimal age to recommend MCV1. In particular, 339 this model captured several complexities of measles epidemiology, including age-specific 340 contacts, vaccination delays, and VE variations with age of receipt. For every scenario tested, 341 we could identify a unique optimal age in the range of 6–20 months, contrasting the two ages 342 recommended by the WHO. Moreover, we found that the optimal age was governed by 343 location-specific factors, namely transmission level, vaccine coverage, and social contact 344 structure. Overall, our results suggest that, in addition to increasing vaccine coverage, adjusting 345 the recommended vaccination age could help minimize immunity gaps and reduce measles 346 incidence, taking steps toward eventual elimination from endemic settings.

347

A key result from our study is that the optimal age to recommend MCV1 may depend on the local epidemiology of measles. Specifically, we predict that populations suffering from higher measles transmission require a lower vaccination age. More generally, the impact of certain factors of local epidemiology can be understood by considering their effect on the MAI and transmission after vaccine introduction. This explains the effect of pre-vaccination transmission levels (controlled by the parameters R_0 and q), which are correlated with postvaccination transmission levels. Similarly, increasing vaccination coverage is dynamically

equivalent to reducing transmission⁵⁹, hence resulting in higher optimal ages. However, even
at fixed transmission levels, the impact of social contact structure was strong. This result shows
that, in addition to broad metrics quantifying the transmission of measles, detailed knowledge
of social contact structure, quantified by data-derived SCMs, is needed to identify the optimal
in a given population.

360

361 In our simulations, two transmission parameters were required to recapitulate the range of transmission intensities (quantified by the MAI) observed in the pre-vaccine era. Unlike earlier 362 modeling studies^{60,61}, varying only the basic reproduction number was insufficient to reach 363 364 target MAIs for all contact matrices. This discrepancy may be explained by the high age 365 resolution and the inclusion of realistic SCMs in our model. More generally, this result suggests 366 age heterogeneities beyond social contacts are necessary for the design of realistic models of 367 measles. Here, we allowed the relative transmissibility of <5 year olds to vary, and calibrated 368 values varied across multiple orders of magnitude (range: 0.005-46.3). This heterogeneity 369 could also be interpreted as a correction to the SCM, as the SCMs used were derived for more 370 modern populations than the pre-vaccine MAI estimates.

371

372 As the main goal of our study was to establish a proof of concept, we chose the minimization 373 endpoint of equilibrium incidence to estimate the optimal age in endemic settings. In real-world 374 applications, however, this endpoint should be defined over shorter time scales, reflecting the 375 time frame of control, and should be reassessed frequently as the optimal ages change with 376 decreasing transmission. Additionally, other endpoints like hospitalization or deaths may be 377 considered but will require extending our model to represent additional mechanisms of vaccine 378 protection, such as reduced disease severity in vaccine-breakthrough cases⁶². Importantly, considering other endpoints may change the nature of the trade-off in risks, in particular 379

because of the increased incentive to vaccinate early if mortality is increased in younger ages⁶³.
Similarly, other endpoints, like the risk of invasion, will be needed to estimate the optimal age
in elimination settings, where vulnerability to outbreaks may persist due to residual pockets of
susceptible individuals⁶⁴. Applying our model in such settings will require a stochastic
formulation, due to the low number of cases and frequent extinctions that deterministic models
cannot capture well.

Furthermore, the real-world application of our method will require additional components 387 388 beyond population-specific information on the SCM, vaccine coverage, and delay distribution, 389 to fully characterize measles epidemiological dynamics in a target population. These include 390 demography, as changes in population structure are expected to affect age-specific 391 transmission dynamics⁶⁵, with more circulation expected in younger populations⁶⁶. A second 392 key component is seasonality in transmission, which can result from term-time increases in contacts among school-aged children⁶⁷ or the effect of climate on virus transmissibility⁶⁸. 393 394 Therefore, a prerequisite to applying our method is a detailed model—identified, for example, 395 by fitting to long-term incidence data using modern statistical inference techniques⁴⁹—for 396 capturing the local drivers of measles transmission.

397

Another key consideration when applying our proposed method is SIAs. These additional immunization campaigns aim to rapidly increase population immunity by vaccinating target demographics—typically children aged ≤ 14 years—regardless of vaccination history⁶⁹. In general, such campaigns are expected to reduce transmission and, thus, increase the optimal age for MCV1. Hence, in settings where SIAs are routinely administered, MCV1 age should be optimized to maximize the effect of both interventions.

³⁸⁶

405 Beyond the components listed above, our method could be extended to consider the effects of 406 MCVs on other pathogens. Indeed, measles infection can cause immune amnesia, whereby the 407 suppression of immune cells partially erases immune memory to previously encountered 408 pathogens⁷⁰. As a result, MCVs have beneficial indirect effects on other infectious diseases⁷¹. 409 In addition, it has been proposed that MCVs directly affect non-measles pathogens, perhaps 410 because of enhanced trained immunity⁷². Beyond MCVs, our proposed method could also be 411 applied to estimate the optimal age for vaccines against other childhood infections. We expect 412 the relationship between vaccination age and VE to be qualitatively similar for other vaccines, 413 even though the empirical evidence has remained more limited than for measles^{73,74}. As the 414 measles vaccine is often combined with the mumps and rubella vaccines (MMR), the natural 415 next candidates would be these two vaccines. Because mumps and rubella infection have 416 different transmissibility than measles (Mumps R_0 : 4–7⁷⁵, Rubella R_0 : 6–7⁷⁵), the risk trade-417 off underlying the optimal age is expected to differ. Hence, a future research question is how 418 to extend our approach to identify the optimal age for combined vaccines.

419

420 Despite the availability of effective vaccines for over 60 years, measles remains a considerable 421 threat in many countries. Here, we propose that, alongside ever-necessary efforts to increase 422 vaccine coverage, another effective intervention to reduce measles cases may be to tailor the 423 vaccination age. Hence, our results suggest the scope for public health authorities to improve 424 measles control and reach for eventual elimination by customizing the recommended 425 vaccination schedule. More generally, as the trade-off underlying the optimal age is not specific 426 to measles, our results could have ramifications for controlling many other vaccine-preventable 427 diseases.

429 **References:**

- 430 1. Paules, C. I., Marston, H. D. & Fauci, A. S. Measles in 2019 Going Backward. N. Engl.
- 431 *J. Med.* **380**, 2185–2187 (2019).
- 432 2. Wang, R., Jing, W., Liu, M. & Liu, J. Trends of the Global, Regional, and National
- 433 Incidence of Measles, Vaccine Coverage, and Risk Factors in 204 Countries From 1990 to
- 434 2019. Front. Med. 8, (2022).
- 435 3. Langmuir, A. D. Medical Importance of Measles. *Am. J. Dis. Child.* **103**, 224–226 (1962).
- 436 4. Dixon, M. G. et al. Progress Toward Regional Measles Elimination Worldwide, 2000–
- 437 2020. Morb. Mortal. Wkly. Rep. 70, 1563–1569 (2021).
- 438 5. World Health Organization. Measles fact sheet. World Health Organization
- 439 https://www.who.int/news-room/fact-sheets/detail/measles (2023).
- 6. World Health Organization. Measles and rubella strategic framework 2021-2030. *Measles*
- 441 *and rubella strategic framework: 2021-2030* https://www.who.int/publications-detail-
- 442 redirect/measles-and-rubella-strategic-framework-2021-2030 (2020).
- 443 7. Causey, K. et al. Estimating global and regional disruptions to routine childhood vaccine
- 444 coverage during the COVID-19 pandemic in 2020: a modelling study. *The Lancet* **398**,

445 522–534 (2021).

- 446 8. World Health Organization. Measles Reported cases by country. *Global Health*
- 447 *Observatory data repository* https://apps.who.int/gho/data/view.main.1540_62?lang=en
 448 (2021).
- 449 9. Hughes, S. L. *et al.* The effect of time since measles vaccination and age at first dose on
 450 measles vaccine effectiveness A systematic review. *Vaccine* 38, 460–469 (2020).
- 451 10. Gans, H. et al. Measles and mumps vaccination as a model to investigate the
- 452 developing immune system: passive and active immunity during the first year of life.
- 453 *Vaccine* **21**, 3398–3405 (2003).

- 454 11. Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in
- 455 humans from infancy to old age. *Proc. R. Soc. B Biol. Sci.* **282**, 20143085 (2015).
- 456 12. McLean, A. R. & Anderson, R. M. Measles in developing countries Part I.
- 457 Epidemiological parameters and patterns. *Epidemiol. Infect.* **100**, 111–133 (1988).
- 458 13. Mclean, A. R. & Anderson, R. M. Measles in developing countries. Part II. The
- 459 predicted impact of mass vaccination. *Epidemiol. Infect.* **100**, 419–442 (1988).
- 460 14. World Health Organisation. WHO Immunization Data portal.
- 461 https://immunizationdata.who.int/compare.html?COMPARISON=type1__WIISE/MT_AD
- 462 _COV_LONG+type2__WIISE/MT_AD_INC_RATE_LONG+option1__MCV_coverage+
- 463 option2__MEASLES_incidence&GROUP=Countries&YEAR=.
- 464 15. United Nations Development Program. Human Development Reports: Data
- 465 *downloads. Human Development Reports* https://hdr.undp.org/data-center/documentation466 and-downloads.
- 467 16. World Health Organisation. Vaccination schedule for Measles. *World Health*
- 468 Organisation https://immunizationdata.who.int/pages/schedule-by-

disease/measles.html?ISO_3_CODE=&TARGETPOP_GENERAL= (2021).

- 470 17. European Centre for Disease Prevention and Control. Measles: Recommended
- 471 vaccinations. Vaccine Scheduler https://vaccine-
- 472 schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdB
 473 yDisease=-1 (2023).
- 474 18. Rochmyaningsih, D. Indonesian 'vaccine fatwa' sends measles immunization rates
- 475 plummeting. Science News https://www.science.org/content/article/indonesian-vaccine-
- 476 fatwa-sends-measles-immunization-rates-plummeting (2018).
- 477 19. Ministerio de Salud y Deportes de Bolivia. Esquema Nacional de Vacunación 2018.
- 478 *Ministerio de Salud y Deportes* https://www.minsalud.gob.bo/es/42-pai/3067-esquema-de-

- 479 vacunacion (2018).
- 480 20. Centers for Disease Control and Prevention. About Measles Vaccination | CDC.
- 481 *Vaccines and Preventable Diseases* https://www.cdc.gov/vaccines/vpd/measles/index.html
- 482 (2022).
- 483 21. Public Health Agency of Canada. Recommended immunization schedules: Canadian
- 484 Immunization Guide. https://www.canada.ca/en/public-
- 485 health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-
- 486 immunization-information/page-13-recommended-immunization-schedules.html (2007).
- 487 22. UNICEF. Know your child's immunization schedule | UNICEF India. UNICEF India
- 488 https://www.unicef.org/india/know-your-childs-immunization-schedule.
- 489 23. KDCA. KDCA. KDCA https://www.kdca.go.kr.
- 490 24. Chapter 6: Choosing effect measures and computing estimates of effect. in *Cochrane*
- 491 Handbook for Systematic Reviews of Interventions version 6.4 (eds. Julian PT Higgins,

492 Tianjing Li, & Jonathan J Deeks) (Cochrane, 2023).

- 493 25. Pya, N. & Wood, S. N. Shape constrained additive models. *Stat. Comput.* 25, 543–559
 494 (2015).
- 495 26. Ruppert, D., Wand, M. P. & Carroll, R. J. *Semiparametric Regression*. (Cambridge
 496 University Press, 2003).
- 497 27. Clark, A. & Sanderson, C. Timing of children's vaccinations in 45 low-income and
 498 middle-income countries: an analysis of survey data. *The Lancet* 373, 1543–1549 (2009).
- 499 28. Lomax, K. S. Business Failures: Another Example of the Analysis of Failure Data. *J.*500 *Am. Stat. Assoc.* 49, 847–852 (1954).
- 501 29. Leonard Kaufman & Peter J. Rousseeuw. Partitioning Around Medoids (Program
- 502 PAM). in *Finding Groups in Data* 68–125 (John Wiley & Sons, Ltd, 1990).
- 503 doi:10.1002/9780470316801.ch2.

- 30. Kaufman, L. & Rousseeuw, P. J. *Finding Groups in Data*. (John Wiley & Sons, Inc.,
 2005).
- 506 31. Tibshirani, R., Walther, G. & Hastie, T. Estimating the number of clusters in a data
 507 set via the gap statistic. *J. R. Stat. Soc. Ser. B Stat. Methodol.* 63, 411–423 (2001).
- 508 32. Bjørnstad, O. N., Finkenstädt, B. F. & Grenfell, B. T. Dynamics of Measles
- 509 Epidemics: Estimating Scaling of Transmission Rates Using a Time Series Sir Model.
- 510 *Ecol. Monogr.* **72**, 169–184 (2002).
- 511 33. Grenfell, B. T., Bjørnstad, O. N. & Finkenstädt, B. F. Dynamics of Measles
- 512 Epidemics: Scaling Noise, Determinism, and Predictability with the Tsir Model. *Ecol.*
- 513 *Monogr.* **72**, 185–202 (2002).
- 514 34. Mistry, D. et al. Inferring high-resolution human mixing patterns for disease
- 515 modeling. *Nat. Commun.* **12**, 323 (2021).
- 516 35. Mossong, J. et al. Social Contacts and Mixing Patterns Relevant to the Spread of
- 517 Infectious Diseases. *PLOS Med.* 5, e74 (2008).
- 518 36. Verguet, S. et al. Controlling measles using supplemental immunization activities: A
- 519 mathematical model to inform optimal policy. *Vaccine* **33**, 1291–1296 (2015).
- 520 37. Anderson, R. & May, R. Vaccination against rubella and measles: Quantitative
- 521 investigations of different policies. J. Hyg. (Lond.) 90, 259–325 (1983).
- 522 38. Galanti, M. *et al.* Rates of asymptomatic respiratory virus infection across age groups.
 523 *Epidemiol. Infect.* 147, e176 (2019).
- 524 39. Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID525 19 epidemics. *Nat. Med.* 26, 1205–1211 (2020).
- 526 40. Soetaert, K., Petzoldt, T. & Setzer, R. W. Solving Differential Equations in R:
- 527 Package deSolve. J. Stat. Softw. 33, 1–25 (2010).
- 528 41. R Core Team. R: A Language and Environment for Statistical Computing. (2022).

- 529 42. Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4, 1686 (2019).
- 530 43. Kim, S. ppcor: Partial and Semi-Partial (Part) Correlation. (2015).
- 531 44. Pya, N. scam: Shape Constrained Additive Models. (2022).
- 532 45. Nocedal, J. & Wright, S. J. Numerical Optimization. (Springer, 2006).
- 533 46. Byrd, R. H., Lu, P., Nocedal, J. & Zhu, C. A Limited Memory Algorithm for Bound
- 534 Constrained Optimization. *SIAM J. Sci. Comput.* **16**, 1190–1208 (1995).
- 535 47. Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M. & Hornik, K. cluster: Cluster
- 536 Analysis Basics and Extensions. https://cran.r-
- 537 project.org/web/packages/cluster/citation.html (2022).
- 538 48. Kassambara, A. & Mundt, F. factoextra: Extract and Visualize the Results of
- 539 Multivariate Data Analyses. (2020).
- 540 49. King, A. A., Nguyen, D. & Ionides, E. L. Statistical Inference for Partially Observed
- 541 Markov Processes via the R Package pomp. J. Stat. Softw. 69, 1–43 (2016).
- 542 50. Rowan, T. Functional stability analysis of numerical algorithms. in (1990).
- 543 51. NLopt NLopt Documentation. https://nlopt.readthedocs.io/en/latest/.
- 544 52. Bates, D. et al. lme4: Linear Mixed-Effects Models using 'Eigen' and S4. (2022).
- 545 53. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlang, 2016).
- 546 54. Garnier, S. *et al.* sjmgarnier/viridis: viridis 0.6.0 (pre-CRAN release). (2021)
- 547 doi:10.5281/zenodo.4679424.
- 548 55. Ram, K., Wickham, H., Richards, C. & Baggett, A. wesanderson: A Wes Anderson
- 549 Palette Generator. (2018).
- 550 56. Pedersen, T. L. patchwork: The Composer of Plots. (2022).
- 551 57. Brand, T. van den. ggh4x: Hacks for 'ggplot2'. (2023).
- 552 58. Guerra, F. M. et al. The basic reproduction number (R0) of measles: a systematic
- 553 review. Lancet Infect. Dis. 17, e420–e428 (2017).

- 554 59. Earn, D. J. D., Rohani, P., Bolker, B. M. & Grenfell, B. T. A Simple Model for
- 555 Complex Dynamical Transitions in Epidemics. *Science* **287**, 667–670 (2000).
- 556 60. Magpantay, F. M. G., King, A. A. & Rohani, P. Age-structure and transient dynamics
- in epidemiological systems. J. R. Soc. Interface 16, 20190151 (2019).
- 558 61. Farrington, C. P., Kanaan, M. N. & Gay, N. J. Estimation of the Basic Reproduction
- 559 Number for Infectious Diseases from Age-Stratified Serological Survey Data. J. R. Stat.
- 560 Soc. Ser. C Appl. Stat. 50, 251–292 (2001).
- 561 62. Fappani, C. et al. Breakthrough Infections: A Challenge towards Measles
- 562 Elimination? *Microorganisms* **10**, 1567 (2022).
- 563 63. Sbarra, A. N. et al. Estimating national-level measles case-fatality ratios in low-
- income and middle-income countries: an updated systematic review and modelling study.
- 565 *Lancet Glob. Health* **11**, e516–e524 (2023).
- 566 64. Kohnen, M. et al. Diagnostic challenges and pockets of susceptibility identified
- during a measles outbreak, Luxembourg, 2019. *Eurosurveillance* **26**, 2000012 (2021).
- 568 65. Graham, M. *et al.* Measles and the canonical path to elimination. *Science* 364, 584–
 569 587 (2019).
- 570 66. Geard, N. et al. The effects of demographic change on disease transmission and
- 571 vaccine impact in a household structured population. *Epidemics* **13**, 56–64 (2015).
- 572 67. Keeling, M. J. & Rohani, P. Modeling Infectious Diseases in Humans and Animals.
- 573 *Modeling Infectious Diseases in Humans and Animals* (Princeton University Press, 2011).
- doi:10.1515/9781400841035.
- 68. de Jong, J. G. The survival of measles virus in air, in relation to the epidemiology of
 measles. *Arch. Für Gesamte Virusforsch.* 16, 97–102 (1965).
- 577 69. World Health Organization. Planning and implementing high-quality supplementary
- 578 immunization activities for injectable vaccines using an example of measles and rubella

- 579 vaccines: field guide. https://www.who.int/publications-detail-redirect/9789241511254
- 580 (2016).
- 581 70. Mina, M. J. *et al.* Measles virus infection diminishes preexisting antibodies that offer
 582 protection from other pathogens. *Science* 366, 599–606 (2019).
- 583 71. Mina, M. J., Metcalf, C. J. E., de Swart, R. L., Osterhaus, A. D. M. E. & Grenfell, B.
- 584 T. Long-term measles-induced immunomodulation increases overall childhood infectious
- 585 disease mortality. *Science* **348**, 694–699 (2015).
- 586 72. Aaby, P. et al. The optimal age of measles immunisation in low-income countries: a
- secondary analysis of the assumptions underlying the current policy. *BMJ Open* **2**,
- 588 e000761 (2012).
- 589 73. Galil, K., Fair, E., Mountcastle, N., Britz, P. & Seward, J. Younger Age at
- 590 Vaccination May Increase Risk of Varicella Vaccine Failure. *J. Infect. Dis.* 186, 102–105
 591 (2002).
- 592 74. Redd, S. C. et al. Comparison of Vaccination with Measles-Mumps-Rubella Vaccine
- 593 at 9, 12, and 15 Months of Age. J. Infect. Dis. 189, S116–S122 (2004).
- 594 75. Emilia Vynnycky & Richard G White. An introduction to infectious disease
- 595 modelling EMILIA VYNNYCKY and RICHARD G WHITE.
- 596 https://anintroductiontoinfectiousdiseasemodelling.com/.
- 597

598 Data availability / Code availability:

599 Code will be deposited in the Open Research Data Repository of the Max Planck Society,

601

602 Acknowledgements:

- 603 This work was supported by the Max Planck Society (Berlin, Germany). Computations were
- 604 performed at the Max Planck Computing and Data Facility (MPCDF). We thank Professor
- 605 Pejman Rohani for his valuable feedback on the manuscript.
- 606

607 Author contributions:

- 608 EG and MDdC conceptualized the project, and designed the methods. Implementation was
- 609 carried out by EG, and reviewed by LABG. EG and MDdC wrote the manuscript, with support

610 from MB and LABG. MDdC supervised the project.

⁶⁰⁰ Edmond (<u>https://edmond.mpg.de</u>), before publishing.

612 Figures:



Figure 1: Trade-off in risks and resulting framework for calculating the optimal age to recommend MCV1. a) Illustration of the risk trade-off that should be balanced when recommending MCV1 age. b) Conceptual framework for calculating the optimal age to recommend MCV1. Gray boxes indicate variables used to parameterize the mechanistic model of measles transmission and vaccination. Values in brackets indicate the number of variants used. The yellow dots and box reflect incidence, the blue arrow and line the minimization of the incidence, and red indicates the age at minimum incidence, the optimal age.





Figure 2: Map and distribution of recommended MCV1 ages. Reported recommended 622 MCV1 ages by country, from the WHO¹⁶, ECDC¹⁷, and country-based reporting^{18–23}. The 623 624 histogram indicates the number of countries recommending MCV1 vaccination at each age. 625



Figure 3: The impact of recommended MCV1 age on the effective vaccine coverage. a) 627 628 MCV1 effectiveness with age of receipt. VE estimates are indicated with points, with vertical 629 lines indicating the 95% confidence interval and horizontal lines indicating uncertainty in MCV1 age. The SCAM model is indicated in gray; the shaded area indicates the approximate 630 631 simultaneous 95% confidence interval, and the lines indicate the 2.5%, 25%, MLE, 75%, and 97.5% quantiles. b) Cumulative delay distributions. Cluster medoids are bolded, with points 632 showing the associated delay data. c) Cumulate effective MCV1 coverage when recommending 633 634 MCV1 at 6, 9, and 12 months, with long delay distribution. Cumulative vaccine coverage after 24 months is set to 100%. Dashed lines indicate the MCV1 coverage, points indicate the 635 636 effective MCV1 coverage, with vertical lines indicating the 95% confidence intervals. d) 637 Cumulative effective MCV1 coverage at 18 months when recommending MCV1 at 6, 9, and

- 638 12 months, for long and short delay distributions. Points indicate MLE estimates, and vertical
- 639 lines indicate the 95% confidence intervals.





642 Figure 4: Basic reproductive number and relative <5 years transmissibility for 7 social 643 contact matrices. For each SCM, the left-hand plots show the social contact rate between age groups. In the corresponding right-hand plots, points indicate the fitted values of R_0 and q for 644 each target MAI, with larger points indicating the values selected to parameterize the 645 646 mechanistic model. Transmission levels are indicated by point shape. For clarity, medium-647 transmission level points are not shown.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.20.23298759; this version posted November 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .





649 Figure 5: Estimating the optimal age to recommend measles vaccination. a) Estimated 650 annual incidence when recommending MCV1 at ages 6-20 months, with 45% MCV1 651 coverage. Each line indicates the relative incidence for a given parameter set, relative to the 652 minimum incidence for that parameter set. b) Heatmap of optimal ages. Opacity indicates the 653 proportion of parameter sets with an optimum in a given MCV1 age. For clarity, the results for 55% and 75% vaccination coverage are not displayed. 654

656 **Tables:**

SCM	Optimal age	Incidence at the	% Increased incidence		
		optimal age	9 months	12 months	
China	10 (9, 12)	747 (729, 766)	0 (0, 1)	0 (0, 1)	High
India	7 (6, 8)	823 (796, 856)	1 (0, 2)	4 (3, 7)	transmission,
Japan	9 (7, 10)	784 (752, 824)	0 (0, 1)	2 (1, 4)	coverage
Moscow	9 (7, 10)	782 (754, 815)	0 (0, 1)	2 (1, 4)	
South Africa	6 (6, 7)	846 (820, 876)	2 (1, 3)	6 (4, 8)	
UK	7 (6, 8)	814 (782, 852)	1 (0, 2)	5 (3, 8)	
USA	8 (7, 9)	796 (766, 832)	0 (0, 1)	3 (1, 5)	
China	17 (15, 20)	169 (124, 196)	15 (8, 30)	4 (2, 11)	Low
India	13 (11, 15)	205 (159, 237)	7 (2, 14)	1 (0, 2)	transmission,
Japan	16 (14, 19)	173 (126, 203)	14 (7, 28)	4 (1, 10)	coverage
Moscow	16 (13, 19)	174 (125, 208)	13 (6, 27)	3 (0, 11)	
South Africa	13 (11, 15)	206 (151, 244)	6 (1, 16)	1 (0, 3)	
UK	13 (12, 16)	190 (141, 223)	9 (3, 19)	1 (0, 4)	
USA	16 (13, 18)	181 (133, 212)	12 (6, 25)	3 (0, 8)	

657 Table 1: Estimated optimal ages and annual incidences. Optimal age indicates the mean (95% confidence interval) of the optimal ages from all parameter sets for the scenario. 658 Incidence indicates the mean (95% confidence interval) annual incidence per 100,000 of the 659

- 660 parameter sets at the optimal ages. Percentage increased incidence reflects the mean of the
- 661 incidence increase compared to the optimal age incidence.